Sector Indices

Name Value Change %
BSE Carbonex 1,114.93 3.6 0.3
BSE Greenex 1,823.20 6.1 0.3
BSE SME IPO 840.13 [12.4] [1.5]
BSE 100 6,864.07 21.9 0.3
BSE 200 2,743.71 8.6 0.3
BSE 500 8,512.09 26.8 0.3
BSE AUTO 13,632.16 17.5 0.1
 

Apollo Hospitals (Q2 FY13)

India Infoline Research Team / 12:03 , Nov 19, 2012

CMP Rs835, Target Rs900, Upside 7.8%

  • Apollo Hospitals recorded standalone revenues growth of 20.7% yoy to Rs.8.5bn, largely in line with our estimates. Consolidated revenue grew by 22.6% yoy to Rs9.6bn driven by strong growth in retail pharmacy (+33.2%) and hospitals biz (+15.5%).

  • Chennai cluster recorded growth of 11% yoy in to Rs2.5bn led by strong ARPOB growth on the back of better case mix and pricing. Hyderabad clusters’ revenues grew by 13% yoy to Rs1.1bn. Other Hospitals outside of Chennai & Hyderabad (Bhubaneshwer, Madurai, Mysore etc) also displayed strong growth. Apollo’s newer hospitals continued to display steady progress and improvement in operating parameters. Bhubaneswars’ occupancy was at 189 beds (76% utilization on an increased capacity of 250 beds) as compared to 127 beds in H1FY12. Apollo REACH Hospitals at Karimnagar and Karaikudi also performed well with revenue growth of 171% and 288% respectively.

  • Apollo Pharmacies (SAPs) added 56 stores and closed down 14 stores, in Q2FY13 leading to total capacity of  1,399 operational stores currently. Revenue growth on an overall basis continued post robustg gorth (+33.2% to Rs2.8bn) in Q2FY13. The business also reported further improvements in profitability with an EBITDA doubling yoy to Rs81 in Q2FY13.

  • Apollo Munich achieved a gross written premium of Rs.2.1bn in Q2 FY13 representing a growth of 38% yoy. Similarly, the earned premium demonstrated traction expanding 54% to Rs1.5bn. The claim loss ratio has been sustained at 58% even in this quarter. With assets under management of Rs4.4 bn, the business has turned finally PAT positive in Q2FY13 by reporting Net Profit of Rs3.6mn as compared to a loss of Rs71mn in Q2 FY12.

  • Consolidated EBITDA was up by 25.9% yoy to Rs1.6bn whereas stadalone operating profit was up by 23% yoy to Rs1.4bn. The margin expanded by 50 bps yoy to 17.2% aided by expansion in margin in Healthcare services , improved operating income contribution by SAPs and positive EBITDA of  Apollo Munich health insurance.

  • Apollo reported better than expected growth in PAT. Consolidated PAT grew 52.2% to Rs838mn in Q2 FY13 whereas Standalone PAT grew by 49.3% yoy to Rs832mn. The growth was largely led by lower taxes on account of effective tax rate lower at 26% along with higher other income.

Quarterly Business mix
Particulars Q2FY13 Q2FY12 %yoy Q1FY13 % qoq
Income From Each segment        
Healthcare Services 5,589 4,915 13.7 5,299 5.5
Pharmacy 2,776 2,085 33.2 2,477 12.1
Others 144 64 125.2 41 253.1
Less: Inter-segmental Revenue 2 2 - 2 -
Total 8,507 7,061 20.5 7,815 8.9
Profit before Tax and Int          
Healthcare Services 1,111 926 20.0 1,015 9.5
Pharmacy 59 17 243.3 38 54.9
Others 144 64 125.2 41 253.1
Less:Interest 188 178 6.1 137 37.8
PBT 1,125 829 35.7 957 17.6
Capital Employed          
Healthcare Services 26,888 20,638 30.3 24,201 11.1
Pharmacy 2,935 2,472 18.7 2,843 3.2
Others 5,344 5,326 0.4 3,566 49.9
Total 35,167 28,436 23.7 30,610 14.9
Source: Company, India Infoline Research

Results table (Standalone)
QUARTERLY -(Rs. in Mn.) Q2FY13 Q2FY12 % yoy Q1FY13 % qoq
Net Sales 8,363 6,998 19.5 7,774 7.6
(Inc)/Decrease in stock (36) (31) 18.6 (218) (83.3)
Material consumption (2,134) (1,977) 7.9 (2,230) (4.3)
Purchase of Traded Goods (2,255) (1,670) 35.0 (1,985) 13.6
Staff Cost (1,305) (1,095) 19.2 (1,257) 3.8
Other Expenditure (1,035) (962) 7.6 (1,075) (3.7)
Selling & Distribution Exp (231) (154) 50.0 (140) 64.5
Operating Profit 1,440 1,170 23.0 1,304 10.4
OPM (%) 17.2 16.7 49 bps 16.8 44 bps
Depreciation (270) (228) 18.6 (251) 7.5
Interest (184) (178) 3.8 (137) 34.9
Other Income 144 64 125.2 40.7 253.1
PBT 1,129 829 36.2 957 18.0
Income Tax (293) (271) 7.9 (259) 12.9
Reported PAT 836 558 50.0 697 19.9
Effective tax rate (%) 25.9 32.7 (680) bps 27.1 (117) bps
Annualised Diluted  EPS 6.0 4.2 41.7 5.1 17.1
Source: Company, India Infoline Research

Outlook:

We expect robust performance in healthcare services business with capacity being ramped up over the next three years. With focus on Increasing ARPOB through reduced ALOS, pricing and case-mix improvement we expect earning momentum to continue. In the pharmacy business, we believe increase in the private label goods will increase the margins and profitability further. We value Apollo on a SOTP basis and assign MP rating with a revised 9-month target price of Rs900. Please note that the downgrade to MP from BUY is solely based on limited upside based on valuation parameter. We continue to remain positive on the company.


Financial summary
Y/e 31 Mar (Rs m) FY11 FY12 FY13E FY14E
Revenues 26,054 31,475 40,703 48,008
yoy growth (%) 28.6 20.8 29.3 17.9
Operating profit 4,189 5,131 6,938 8,629
OPM (%) 16.1 16.3 17.0 18.0
Reported PAT 1,839 2,194 3,147 3,512
yoy growth (%) 33.7 19.3 43.5 11.6
         
EPS (Rs) 14.7 16.3 23.4 26.1
P/E (x) 56.6 51.2 35.7 32.0
Price/Book (x) 5.5 4.5 4.1 3.7
EV/EBITDA (x) 26.7 23.1 17.9 14.9
Debt/Equity (x) 0.5 0.3 0.5 0.7
RoE (%) 10.4 10.0 12.0 12.2
RoCE (%) 12.2 12.8 14.2 14.5
Source: Company, India Infoline Research